RCS - Tristel PLC - APIC25 Annual Conference attendance

TristelAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250626:nRSZ4563Oa&default-theme=true

RNS Number : 4563O  Tristel PLC  26 June 2025

TRISTEL plc

("Tristel" or the "Company")

 

APIC25 Annual Conference attendance

 

Tristel Exhibits at the Largest Annual Infection Prevention Event in the U.S.
and Launches Tristel OPH Following FDA Clearance

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces its successful participation at APIC 2025, the largest annual
infection prevention and control conference in the United States, and the
official U.S. launch of Tristel OPH, a novel high-level disinfectant for
ophthalmic instruments, following clearance by the U.S. Food and Drug
Administration (FDA).

 

APIC 2025 provided a high-impact platform for Tristel to introduce Tristel OPH
to the U.S. market. The product addresses a significant unmet need in
ophthalmology, offering a solution that combines compliance with infection
control guidelines and improved clinical workflow efficiency. Its debut
generated exceptional interest from infection prevention professionals,
reflecting the urgency for effective, practical alternatives in the
reprocessing of ophthalmic medical devices.

 

A robust pipeline of prospective customers has already been established, with
many health systems engaging directly with the Tristel team during the event
for live demonstrations and discussions on product evaluation. Stock
availability is expected in August 2025, and Tristel is actively supporting
U.S. institutions in preparing for clinical trials and internal validation
upon launch.

 

In addition to Tristel OPH, the Company also showcased Tristel ULT, its
FDA-cleared high level disinfectant for ultrasound probes, represented by
Tristel's distribution partner and ultrasound specialist, Parker Laboratories,
Inc., and Tristel 3T, the Company's digital traceability platform. Both
products attracted strong interest from new prospects and existing users
alike, with particular enthusiasm shown for Tristel ULT's cost-effectiveness
and rapid reprocessing capabilities.

 

The strong reception at APIC 2025 reinforces Tristel's accelerating momentum
in the U.S. and underlines the increasing demand for innovative and compliant
high level disinfection solutions in medical device reprocessing.

 

 [

 

Matt Sassone, CEO of Tristel plc, said: "APIC 2025 marked a significant
milestone for our U.S. strategy. The FDA clearance and now successful launch
of Tristel OPH opens a valuable new market in ophthalmology and demonstrates
our ability to deliver meaningful innovation where it's urgently needed. The
response to both Tristel OPH and Tristel ULT was overwhelmingly positive, and
we are excited about the opportunities ahead."

 

 

For further information please contact:

 

 Tristel plc                                                Via Walbrook PR
 Matt Sassone, Chief Executive Officer                      https://investors.tristel.com/ (https://investors.tristel.com/)
 Liz Dixon, Chief Financial Officer

 Walbrook PR Ltd                                            Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus / Lianne Applegarth  Mob: 07980 541 893/ 07584 391 303

 Cavendish Capital Markets Ltd                              Tel: 020 7220 0500
 Geoff Nash / Trisyia Jamaludin / Callum Davidson (Corporate Finance)
 Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, a more sustainable alternative to commonly used
pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets annual revenue
growth of between 10% and 15% and an EBITDA margin of at least 25% and the
business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABCGDLDSDDGUU